Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01329185 · ClinicalTrials.gov registry record · Phase 2
Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
A Phase 2 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT01329185 is a Phase 2 study that has completed, run by University of Minnesota. The registered enrollment target is 17 participants.
The verdict
NCT01329185, a Phase 2 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The aim of our study is to reduce viral (CMV and EBV) transmission from donor to recipient. The discovery that anti-retroviral therapy to mothers with HIV reduced transmission of the virus to their babies was pivotal to the prevention of AIDS and so along the same lines the investigators will test the hypothesis that 14 days of the anti-viral Valganciclovir (VAL) to kidney donors prior to the transplant compared to placebo will reduce EBV and CMV viremia in the 1st year posttransplant in pediatric kidney recipients.
Interventions
- DRUG Placebo
- DRUG Valganciclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2011-06 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01329185
The ClinicalTrials.gov registry entry for NCT01329185 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01329185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01329185 about?
NCT01329185 is a clinical study titled "Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients". The aim of our study is to reduce viral (CMV and EBV) transmission from donor to recipient. The discovery that anti-retroviral therapy to mothers with HIV reduced transmission of the virus to their babies was pivotal to the prevention of AIDS and so along the same lines the investigators will test t...
What is the current status of trial NCT01329185?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2011-06. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01329185?
The interventions under investigation include: Placebo (DRUG), Valganciclovir (DRUG).
Who is sponsoring clinical trial NCT01329185?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.